Thrifty White Drug #762, Minneapolis, MN
Is Thrifty White Drug #762 registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Thrifty White Drug #762 hold a Minnesota pharmacy license?
State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.
Has Thrifty White Drug #762 had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (May 27, 2020) and 1 FMD-145 letter (May 27, 2020) for Thrifty White Drug #762. State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Thrifty White Drug #762
- Location
- Minneapolis, MN
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 27, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 6 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Thrifty White Drug #762, a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| May 27, 2020 | State referral letter | State Referral Letter Issued 05/27/2020 | Not linked by FDA |
| May 27, 2020 | FMD-145 letter | FMD-145 Letter Issued 05/27/2020 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Thrifty White Drug #762, Minneapolis, MN (FEI number 3014124016), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 21, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014124016 | 1066265 |
Form 483s FDA has published for this site
- Sep 21, 2018: Form 483 to Thrifty White Drug #762, published Apr 30, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 10, 2018 to Sep 21, 2018: 6 observations
- Firm on the cover
- Thrifty White Drug #762, 6055 Nathan Ln N Ste 200A CITY, STAlE. ZIP CODE COUNTRY Minneapolis, MN 55442-1675
- FEI number
- 3014124016
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- 250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Sporicidal agents were not used in your facility's cleanrooms and/or ISO 5 classified aseptic processing area.
Specifically, on September 10, 2018 we observed your daily cleaning of ISO 5 aseptic processing area was done without the use of any sporicidal agents. We noted that during the cleaning process <Redacted B4> was the only agent used. We also noted that there is no sporicidal agent used in the <Redacted B4> cleaning of the ISO 5 aseptic processing area Your firm stated no sporicidal agent is used in the ISO 5 aseptic processing area.
Observation 2
Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically, On September I 0, 20I8, we observed an employee clean the ISO 5 aseptic processing area with <Redacted B4> , and non-sterile wipes before starting aseptic processing of Cefazolin 2gm/J0OmJ Prescription # <Redacted B4>
Observation 3
Equipment was and Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically, Items are sprayed with <Redacted B4> in the non-classified area of the pharmacy, then transported to the non-class <Redacted B4> which leads directly to the ISO 7 buffer area. These items are then placed into the I~05 aseptic processing area without further disinfection.
Observation 4
The ISO 5 classified aseptic processing areas had difficult to clean equipment or surface.
Specifically, the back of the ISO aseptic processing area does not have a smooth cleanable surface <Redacted B4> it contains <Redacted B4> which include <Redacted B4> type surfaces.
Observation 5
ISO 5 classified areas were not certified under dynamic conditions.
Specifically,
Smoke studies performed in the ISO 5 laminar hood were not performed under dynamic conditions that represent your aseptic processing practices. We observed the aseptic processing of Cefazolin 2gm/l00ml <Redacted B4> which included <Redacted B4> in the ISO 5 hood, using a repeater pump with <Redacted B4> which were not replicated during the smoke studies. There is no video or description provided of the smoke study and no employees of your firm participated or witnessed the smoke study.
Observation 6
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
Specifically, Your firm follows the instructions of the <Redacted B4> media fill kit for risk level-1 (simple procedure) which involved <Redacted B4> contained in the kit and an <Redacted B4> I provided by your firm. We observed the aseptic processing of Cefazolin 2gm/100ml Prescription# <Redacted B4> which included <Redacted B4> in the ISO 5 hood, using a repeater pump with <Redacted B4> be <Redacted B4> media fill kit risk level I procedure does not simulate the batch size or use of repeater pump and <Redacted B4> which are part of your firm's routine conditions.
State board of pharmacy records
State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.